Precise and Robust Immunoprofiling with OmniVUE™ Biomarker Panels leveraging InSituPlex® Assays

Characterization of the tumor microenvironment is critical for discovering evidence of novel treatments’ efficacy. Multiplex immunofluorescence (mIF) assays have emerged as invaluable tools for immune profiling, shedding light on the intricate spatial dynamics within tissues and the interactions between tumor and immune cells. While the potential of mIF assays in clinical translation is widely acknowledged, their successful application hinges on validation, accuracy, precision, and reproducibility. However, a key challenge in this process is finding an mIF assay platform that bridges the need for flexibility in biomarker selection with the demand for robust validation. This study evaluated the sensitivity and reproducibility of biomarker detection using InSituPlex® technology through the completely configurable OmniVUE™ biomarker panels. This platform ensures the reconfigurability in panel design required to rapidly test specific biological hypotheses while maintaining the robustness of a well-validated assay.